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Objectives: To compare rates of unintended pregnancy, method continuation and reasons for removal among women using the 52-mg
levonorgestrel (daily release 20 microg) levonorgestrel IUD (LNG-IUD) or the copper T 380 A (TCu380A) intrauterine device.
Study design: This was an open-label 7-year randomized controlled trial in 20 centres, 11 of which in China. Data on 1884 women with interval
insertion of the LNG-IUD and 1871 of the TCu380A were analysed using life tables with 30-day intervals and Cox proportional hazards models.
Results: The cumulative 7-year pregnancy rate of the LNG-IUD was 0.5 (standard error 0.2) per 100, significantly lower than 2.5 (0.4) per
100 of the TCu380A, cumulative method discontinuation rates at 7 years were 70.6 (1.2) and 40.8 (1.3) per 100, respectively. Dominant
reasons for discontinuing the LNG-IUD were amenorrhea (26.1 [1.3] per 100) and reduced bleeding (12.5 [1.1] per 100), particularly
in Chinese women and, for the TCu380A, increased bleeding (9.9 [0.9] per 100), especially among non-Chinese women. Removal rates for
pain were similar for the two intrauterine devices (IUDs). Cumulative rates of removal for symptoms compatible with hormonal side effects
were 5.7 (0.7) and 0.4 (0.2) per 100 for the LNG-IUD and TCu380A, respectively, and cumulative losses to follow-up at 7 years were 26.0
(1.4) and 36.9 (1.3) per 100, respectively.
Conclusion: The LNG-IUD and the TCu380A have very high contraceptive efficacy, with the LNG-IUD significantly higher than the
TCu380A. Overall rates of IUD removals were higher among LNG-IUD users than TCu380A users. Removals for amenorrhea appeared
culturally associated.☆ The authors declare no conflicts of interest.
☆☆ The authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy or views of theWorld
Health Organization.
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499P. Rowe et al. / Contraception 93 (2016) 498–506Implications: The 52-mg LNG-IUD and the TCu380A have very high contraceptive efficacy through 7 years. As an IUD, the unique side
effects of the LNG-IUD are reduced bleeding, amenorrhea and symptoms compatible with hormonal contraceptives.
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The copper-bearing intrauterine devices (IUDs) and the
levonorgestrel (LNG)-medicated IUD are efficacious revers-
ible contraceptive methods. The copper IUDs were devel-
oped during the 1960s and 1970s, and the copper T Cu380A
(TCu380A) was first approved by the US Food and Drug
Administration (FDA) in 1984 for 4 years of use,
subsequently extended to 10 years in 1994 [1–4]. Develop-
ment of progestogen-medicated IUDs started in the 1970s
and resulted inter alia in drug regulatory approval in Finland
in 1990 of an IUD with a 52-mg LNG load initially releasing
20 microg daily (Levonova®) with a 5-year effective lifespan
[Wahlbom A, Bayer AB, Sweden, Personal communication
2014]. The trials preceding approval in Finland studied LNG
devices loaded with 46 and 60 mg of the hormone, both
releasing 20-microg LNG per day [5–7]. The US FDA
approved the 5-year 52-mg LNG-medicated IUD (Mirena®)
in 2000. In 2013, FDA approved an IUD with 13.5-mg LNG
(Skyla® or Jaydess®) [8] and, in 2015, a new 52-mg
LNG-IUD (Liletta®) [9]. At present, these two new 13.5-
and 52-mg LNG-IUDs both have an approved lifespan of
3 years.
While the TCu380A device had undergone extensive
clinical evaluation, the clinical experience of the LNG-
releasing IUD was limited in the 1990s. Hence, the UNDP/
UNFPA/WHO/World Bank Special Programme of Re-
search, Development and Research Training in Human
Reproduction (HRP) in 1993 initiated a randomized multi-
centre comparative trial in principally developing countries,
of the 52-mg LNG-IUD and the TCu380A to examine the
longer term efficacy and reasons for device removal,
particularly removals for amenorrhea, pain and bleeding,
of the two devices. Interim results from the trial were
published previously [10]. This article gives data on
contraceptive efficacy and reasons for discontinuation of use.2. Material and methods
The study took place in 20 centres in nine countries, 11 of
the centres were in China. The protocol was reviewed by the
Toxicology Panel and the Scientific and Ethical ReviewGroup
ofHRP and theWorldHealthOrganization (WHO) Secretariat
Committee onResearch involvingHumanSubjects. The ethics
committee of participating centres reviewed and approved the
study and where required the appropriate governmental
authority. The trial was planned and initiated before
registration of clinical trials became mandatory.2.1. Devices and training of providers
The LNG-IUD (Mirena™) contains 52-mg LNG and
initially releases 20-microg LNG/day. The device was
manufactured by Leiras Pharmaceutical, Turku, Finland.
The TCu380A (Paragard™) device is T-shaped with a
copper surface area of approximately 380 mm2. The
device was manufactured by Finishing Enterprises, Niagara,
NY, USA.
The LNG-IUD was new to the family planning providers
in the participating centres; hence, an experienced provider
of the LNG-IUD (T. Luukkainen) visited centres to train
physicians and nurses in insertion of the LNG-IUD and
client counselling.
2.2. Admission and randomization
Eligible for the study were healthy informed women, over
16 and under 40 years old, with at least one pregnancy of
≥20 weeks gestation or a foetus delivered weighing
≥500 g, willing to participate and rely solely on the IUD
for contraception, currently cohabiting and able to attend for
follow up at the required intervals. Exclusion criteria were a
history of pelvic inflammatory disease (PID) or pelvic
abscess since last pregnancy, less than 6 weeks since
parturition or abortion, past ectopic pregnancy, recent
sexually transmitted disease, undiagnosed genital tract
bleeding, genital tract malformations, known or suspected
genital tract malignancy, uterine fibromyoma associated
with menstrual disorders, evidence of anaemia and history of
hydatidiform mole in the last pregnancy. After giving
informed consent, each subject provided her medical,
obstetric and gynaecological history.
Each centre received a list of unique trial- and centre-spe-
cific subject numbers consecutively assigned as each woman
was enrolled and a series of sealed envelopes each labelled
with the trial- and centre-specific subject numbers containing
information about the randomly assigned IUD. When device
insertion was due, the envelopewith the corresponding subject
number was opened revealing the assigned IUD. Randomiza-
tion lists were computer-generated by HRP and balanced in
blocks of 10. Since the IUDs were different in appearance and
required different insertion techniques, providers inserting the
device were not masked.
2.3. Follow-up
Scheduled follow-up visits were at 3, 6 and 12months after
insertion and yearly thereafter. Women were instructed to
return to the clinic at any other time if they experienced any
problem and were free to request IUD removal at any time.
1,871 women with 
TCU380A followed up
*All discontinuations, including method discontinuation, release from follow-up or lost to follow-up 
(see details in Table 1).
3,836 eligible consenting women 
1,914 allocated to TCu380A 1,922 allocated to LNG-IUD
3 failed TCu30A insertions 12 failed LNG-IUD insertions
1,911 successful TCu380A 
insertions
1910 successful LNG-
IUD insertions
40 women no follow-up
visits
26 women no follow-up
visits
1,884 women with 
LNG-IUD followed up
284 women 
discontinued* during 1st
or 2nd year of follow-up
393 women 
discontinued* during 1st
or 2nd year of follow-up
317 women  
discontinued* during 3rd
or 4th year of follow-up
491 women  
discontinued* during 3rd
or 4th year of follow-up
281 women  
discontinued* during 5th
or 6th year of follow-up
283 women  
discontinued* during 5th
or 6th year of follow-up
307 women  
discontinued* during 7th
year of follow-up
319 women  
discontinued* during 7th
year of follow-up
682 women with 7 
completed years of 
follow-up
398 women with 7 
completed years of 
follow-up
Fig. 1. Number of women eligible, randomized and followed up in the trial of the 52-mg LNG 20 micro-releasing IUD and the TCu380A IUD.
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use of the LNG-IUD. However, in the course of the trial, the
manufacturer informed that the LNG drug load in the device
might be insufficient for effective contraception after 7 years of
use. The women were informed accordingly, although when
the decision was taken, some women had already completed 8
years. This article is concerned with 7 years follow-up.
2.4. Sample size
Assuming a pregnancy rate of 0.5% at 2 years with the
LNG-IUD, a rate of 2.0% for the TCu380A and a two-sided
95% significance test, a total of 865 subjects completing 2years are required per study group for 80% power or 1159
subjects completing 2 years for 90% power. With an assumed
annual discontinuation rate of 10%, the required total
recruitment to each device was 1430 women for 90% power.
2.5. Data collection, monitoring, outcomes and analysis
Data were recorded on standard precoded forms in
duplicate at admission, at each follow-up visit and at
discontinuation from the study. Forms were sent to the data
coordination centre at WHO in Geneva for data entry.
Clarifications were sought from the individual centres where
necessary. The classification of discontinuation for individual
Table 1
Cumulative numbers and rates per 100 of individual and grouped reasons for IUD discontinuation and loss to follow-up at 1, 3, 5 and 7 years of use by LNG-IUD
and TCu380A IUD in all centres.
Reason for
discontinuation/variable
Year 1 Year 3 3-year rate difference, 95% CI
(TCu380A – LNG-IUD)
LNG-IUD n. 1884 1 TCu380A n. 1871 1 LNG-IUD n. 1491 1 TCu380A n. 1587 1
Events Rate SE Events Rate SE Events Rate SE Events Rate SE
Pregnancies
All 2 0.12 0.08 11 0.64 0.19 6 0.43 0.18 24 1.53 0.31 1.10 (0.39 to 1.80)
Intrauterine 2 0.12 0.08 11 0.64 0.19 6 0.43 0.18 22 1.39 0.30 0.96 (0.28 to 1.64)
Ectopic 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 2 0.14 0.10 0.14 (−0.05 to 0.33)
Expulsions
All 53 2.94 0.40 63 3.49 0.43 82 5.21 0.57 95 5.64 0.57 0.43 (−1.15 to 2.01)
Complete 30 1.66 0.30 14 0.78 0.21 41 2.50 0.39 22 1.34 0.29 −1.16 (−2.11 to −0.21)
Partial 23 1.29 0.27 49 2.73 0.38 41 2.79 0.44 73 4.36 0.50 1.58 (0.27 to 2.89)
Medical
Bleeding problems, all2 160 9.02 0.68 54 3.04 0.41 363 22.81 1.07 96 5.84 0.58 −16.97 (−19.35 to −14.58)
Amenorrhea 72 4.31 0.50 1 0.06 0.06 212 14.49 0.93 1 0.06 0.06 −14.43 (−16.26 to −12.60)
Reduced bleeding3 38 2.23 0.36 10 0.57 0.18 89 6.28 0.66 20 1.25 0.28 −5.03 (−6.43 to −3.63)
Increased bleeding4 50 2.75 0.38 43 2.42 0.37 62 3.68 0.47 75 4.59 0.52 0.92 (−0.45 to 2.29)
Pain 35 2.07 0.35 30 1.72 0.31 59 3.95 0.51 58 3.60 0.47 −0.35 (−1.71 to 1.01)
PID 5 0.29 0.13 0 0.00 0.00 5 0.29 0.13 0 0.00 0.00 −0.29 – –
“Hormonal” reasons5 21 1.25 0.27 1 0.06 0.06 53 3.64 0.50 2 0.12 0.09 −3.52 (−4.51 to −2.53)
End of IUD lifespan 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0.00 – –
Other device-related 4 0.24 0.12 2 0.12 0.08 13 1.02 0.29 9 0.61 0.20 −0.41 (−1.10 to 0.28)
Nondevice-related reasons6 27 1.59 0.30 22 1.28 0.27 97 7.17 0.71 77 5.01 0.56 −2.16 (−3.94 to −0.39)
All IUD discontinuations 307 16.49 0.86 183 9.94 0.70 678 38.23 1.16 361 20.48 0.97 −17.75 (−20.72 to 14.79)
Released from follow-up 11 0.66 0.20 11 0.63 0.19 24 1.66 0.34 22 1.40 0.30 −0.26 (−1.15 to 0.63)
Lost to follow-up 75 4.60 0.52 90 5.22 0.54 182 12.61 0.88 218 13.42 0.85 0.81 (−1.59 to 3.21)
Year 5 Year 7 7-year rate difference
LNG-IUD n. 1000 1 TCu380A n. 1270 1 LNG-IUD n. 717 1 TCu380A n. 989 1
Pregnancies
All 7 0.53 0.21 28 1.85 0.35 7 0.53 0.21 33 2.45 0.44 1.91 (0.97 to 2.86)
Intrauterine 7 0.53 0.21 26 1.72 0.34 7 0.53 0.21 30 2.20 0.41 1.67 (0.76 to 2.57)
Ectopic 0 0.00 0.00 2 0.14 0.10 0 0.00 0.00 3 0.25 0.15 0.25 (−0.04 to 0.55)
Expulsions
All 92 6.30 0.66 115 7.30 0.67 104 8.18 0.84 129 8.84 0.77 0.67 (−1.58 to 2.91)
Complete 43 2.73 0.42 24 1.52 0.31 45 3.01 0.47 26 1.74 0.35 −1.27 (−2.42 to −0.13)
Partial 49 3.67 0.54 91 5.87 0.61 59 5.32 0.74 103 7.23 0.72 1.91 (−0.11 to 3.93)
Medical
Bleeding problems, all2 479 32.40 1.25 143 9.65 0.78 540 39.21 1.41 181 13.76 0.99 −25.45 (−28.83 to −22.08)
Amenorrhea 293 22.00 1.17 1 0.06 0.06 323 26.10 1.33 5 0.52 0.24 −25.59 (−28.24 to −22.94)
Reduced bleeding3 118 9.41 0.86 33 2.34 0.41 139 12.53 1.07 44 3.65 0.56 −8.88 (−11.25 to −6.51)
Increased bleeding4 68 4.33 0.53 109 7.42 0.70 78 5.96 0.73 131 9.91 0.86 3.95 (1.74 to 6.17)
Pain 71 5.28 0.63 75 5.01 0.57 76 6.09 0.73 96 7.37 0.76 1.28 (−0.78 to 3.33)
PID 5 0.29 0.13 1 0.10 0.10 5 0.29 0.13 2 0.21 0.15 −0.08 (−0.46 to 0.31)
Hormonal reasons5 62 4.71 0.61 2 0.12 0.09 68 5.68 0.72 4 0.36 0.19 −5.32 (−6.78 to −3.86)
End of IUD lifespan 0 0.00 0.00 0 0.00 0.00 113 20.38 1.72 0 0.00 0.00 −20.38 (−23.75 to −17.01)
Other device-related 19 1.73 0.41 16 1.24 0.31 28 3.29 0.66 21 1.82 0.40 −1.48 (−2.99 to 0.04)
Nondevice-related reasons6 168 14.68 1.08 141 10.13 0.82 222 22.17 1.39 184 14.64 1.03 −7.54 (−10.93 to −4.14)
All IUD discontinuations 903 52.45 1.22 521 30.84 1.14 1163 70.62 1.17 650 40.81 1.27 −29.81 (−33.19 to −26.43)
Released from follow-up 30 2.36 0.44 32 2.27 0.40 33 2.80 0.51 34 2.48 0.43 −0.32 (−1.63 to 0.99)
Lost to follow-up 234 18.02 1.10 329 21.79 1.08 290 26.02 1.44 505 36.85 1.34 10.83 (6.97 to 14.69)
1 Number of women starting the interval.
2 Including 1 woman with “unclassified bleeding” problems.
3 Reduced bleeding includes reduced, light, infrequent bleeding, spotting, and irregular bleeding.
4 Increased bleeding includes heavy and prolonged bleeding.
5 Hormonal reasons for stopping use is defined in the Methods section.
6 Not device-related reasons include wish for pregnancy, no further need, menopause, and premature removal initiated by investigators for medical
conditions unrelated to use of the IUD.
501P. Rowe et al. / Contraception 93 (2016) 498–506
Table 2
Cumulative numbers and rates per 100 of selected reasons for IUD removal at 1, 3, 5 and 7 years of use by LNG-IUD and TCu380A IUD in Chinese and
non-Chinese centres.
Year
Reason for discontinuation
Chinese centres Non-Chinese centres p-value 1
LNG-IUD TCu380A LNG-IUD TCu380A
Events Rate SE Events Rate SE Events Rate SE Events Rate SE
Year 1
Pregnancies, all 2 0.20 0.14 9 0.89 0.29 0 0.00 0.00 2 0.27 0.19 0.9921
Expulsions, all 30 0.03 0.01 34 0.03 0.01 23 0.03 0.01 29 0.04 0.01 0.6780
Bleeding problems 104 10.24 0.95 16 1.56 0.39 56 7.39 0.95 38 5.06 0.80 b0.0001
Amenorrhea 46 4.81 0.69 1 0.10 0.10 26 3.64 0.70 0 0.00 0.00 0.9839
Reduced bleeding 24 2.48 0.50 2 0.20 0.14 14 1.91 0.51 8 1.09 0.38 0.0206
Increased bleeding 34 3.31 0.56 13 1.27 0.35 16 2.02 0.50 30 4.02 0.72 0.0003
Pain 10 1.02 0.32 11 1.08 0.32 25 3.45 0.68 19 2.63 0.60 0.5672
Nondevice-related reasons 3 0.31 0.18 1 0.10 0.10 24 3.28 0.66 21 2.96 0.64 0.3857
Year 3
Pregnancies, all 6 0.72 0.30 20 2.05 0.45 0 0.00 0.00 4 0.66 0.34 0.9876
Expulsions, all 52 0.06 0.01 55 0.05 0.01 30 0.04 0.01 40 0.06 0.01 0.2786
Bleeding problems 253 26.25 1.43 37 3.75 0.61 110 17.42 1.56 59 9.03 1.15 b0.0001
Amenorrhea 149 16.88 1.27 1 0.10 0.10 63 10.70 1.31 0 0.00 0.00 0.9777
Reduced bleeding 61 7.15 0.89 10 1.04 0.33 28 5.03 0.96 10 1.44 0.46 0.0669
Increased bleeding 43 4.45 0.67 26 2.63 0.51 19 2.62 0.61 49 7.70 1.09 b0.0001
Pain 20 2.33 0.52 15 1.51 0.39 39 6.19 0.99 43 7.07 1.06 0.2105
Nondevice-related reasons 11 1.39 0.42 6 0.63 0.26 86 15.49 1.57 71 12.33 1.40 0.2735
Year 5
Pregnancies, all 6 0.72 0.30 23 2.39 0.49 1 0.29 0.29 5 0.98 0.47 0.6700
Expulsions, all 58 0.07 0.01 69 0.07 0.01 34 0.06 0.01 46 0.08 0.01 0.3458
Bleeding problems 346 37.20 1.60 61 6.51 0.81 133 23.73 1.92 82 15.48 1.69 b0.0001
Amenorrhea 217 26.07 1.54 1 0.10 0.10 76 14.48 1.62 0 0.00 0.00 0.9765
Reduced bleeding 84 10.80 1.14 19 2.09 0.48 34 7.13 1.27 14 2.73 0.78 0.0479
Increased bleeding 45 4.76 0.70 41 4.42 0.68 23 3.98 0.91 68 13.11 1.59 b0.0001
Pain 26 3.35 0.66 20 2.08 0.46 45 8.10 1.24 55 10.63 1.44 0.0746
Nondevice-related reasons 20 2.98 0.67 15 1.72 0.44 148 32.07 2.28 126 26.29 2.10 0.2896
Year 7
Pregnancies, all 6 0.72 0.30 27 3.01 0.58 1 0.29 0.29 6 1.44 0.65 0.6232
Expulsions, all 69 0.09 0.01 80 0.09 0.01 35 0.06 0.01 49 0.09 0.01 0.1934
Bleeding problems 396 44.41 1.72 87 10.17 1.05 144 28.34 2.27 94 21.60 2.33 b0.0001
Amenorrhea 245 31.02 1.70 5 0.70 0.31 78 15.56 1.78 0 0.00 0.00 0.9723
Reduced bleeding 98 13.74 1.35 27 3.28 0.63 41 10.56 1.78 17 4.64 1.34 0.0753
Increased bleeding 53 6.57 0.94 55 6.47 0.86 25 5.12 1.21 76 17.31 2.11 b0.0001
Pain 28 3.78 0.73 29 3.48 0.65 48 9.98 1.64 67 15.80 2.00 0.1179
Nondevice-related reasons 27 4.58 0.89 23 2.94 0.61 195 49.07 2.81 161 38.82 2.62 0.4171
1 p-value for interaction between Chinese and non-Chinese centres by IUD type.
502 P. Rowe et al. / Contraception 93 (2016) 498–506reasons and groups of reasons followed the standard
definitions used for IUD and contraceptive clinical trials,
and used in previous IUD trials by HRP/WHO [1,11–13]. An
additional class of “hormonal reasons” for discontinuation
similar to that reported previously [14], was created to capture
signs and symptoms potentially associated with hormonal
contraception (reasons mentioned by at least one participant
included: abdominal pain, nausea, weight loss or gain, liver
dysfunction, eczema/dermatitis, acne, chloasma, hirsutism, flush-
ing, dizziness, anxiety/nervousness, depression, fatigue, decreased
libido, headaches, adnexal mass, ovarian cyst, breast swelling,
tenderness, breast pain and malignant tumour of the breast).
The cumulative discontinuation rates for each reason and
groups of reasons and their 95% confidence intervals were
computed using the life table method with 30-day intervals,
which approximates the daily Kaplan–Meier method [15].
Tests of interaction of IUD by type of centre (Chinese/non-Chinese) were made using a Cox proportional hazards
regression model with the exact date of discontinuation [16].
All analyses were performed using SAS Version 9.3 [SAS
Institute. SAS/STAT Software, Version 9.3, http://www.sas.
com]. Previous trials of IUDs byHRP that included populations
of Chinese and non-Chinese women showed that event rates
differed between the two populations; hence, stratified analyses
by Chinese and non-Chinese centres were done. Five centres
had cumulative loss to follow-up rates at 7 years above 30%,
and a sensitivity analysis explored whether exclusion of these
five centres affected the overall results of the study.3. Results
Recruitment took place from May 1993 to October 1998.
Altogether, 1914 women were randomized to the TCu380A
All sites Chinese sites Non-Chinese sites
Pregnancy (all)
Expulsion
Amenorrhoea 
Reduced bleeding 
Increased bleeding 
Year Year Year
0.0
2.0
4.0
6.0
8.0
10.0
0 2 4 6
LNG-IUD
TCu 380A
0 2 4 6 0 2 4 6
0.0
2.0
4.0
6.0
8.0
10.0
0 2 4 6
LNG-IUD
TCu 380A
0 2 4 6 0 2 4 6
0.0
10.0
20.0
30.0
0 2 4 6
TCu 380A
0 2 4 6 0 2 4 6
0.0
10.0
20.0
30.0
0 2 4 6
TCu 380A
0 2 4 6 0 2 4 6
0.0
10.0
20.0
30.0
0 2 4 6
LNG-IUD
TCu 380A
0 2 4 6 0 2 4 6
LNG-IUD
LNG-IUD
Fig. 2. Cumulative rates (per 100) of selected reasons for IUD removal by device in all Chinese and non-Chinese centres.
503P. Rowe et al. / Contraception 93 (2016) 498–506and 1922 to the LNG-IUD (Fig. 1). After excluding
IUD-insertion failures and women who never returned to the
clinic, 1871 women with TCu380A (1060 in 11 Chinese
centres, 811 in nine non-Chinese centres) and 1884 with
LNG-IUD (1062 in Chinese centres, 822 in non-Chinese
centres) are included in the analyses (Fig. 1), providing a total of
10,088 and 7903 woman–years of observation, respectively.The mean ages of the women were 29.9 [standard
deviation (SD) = 4.95] and 29.8 (SD = 5.12) years for women
randomized to TCu380A and LNG-IUD, respectively. The
median parity was 1 for both groups with ranges 0–7 and 0–
10, respectively. The median age of Chinese women was
30 years and that of non-Chinese women 29 years. Chinese
women had lower parity (Median 1) than non-Chinese
504 P. Rowe et al. / Contraception 93 (2016) 498–506women (Median 2). Contrary to protocol requirements, a
total of nine women (0.24%, 5 assigned to TCu380A and 4 to
LNG-IUD) were found on review to be nulliparous (prior
abortion [5] or ectopic pregnancy [1], no history of
pregnancy [2], and information missing [1]). These women
have been retained in the analysis.
Table 1 shows cumulative pregnancy and method
discontinuation rates at 1, 3, 5 and 7 years of use for both
devices in all participating centres, overall continuation and
loss to follow-up rates and differences in cumulative rates at
3 and 7 years.
The overall pregnancy rate of the TCu380A was signifi-
cantly higher than that of the LNG-IUD, at the end of the
seventh year the cumulative rate was 2.45 [standard error (SE)
= 0.44] per 100 for the TCu380A and 0.53 (SE = 0.21) per 100
for the LNG-IUD (Table 1). Thirty-three pregnancies occurred
among TCu380A users of which three were ectopic. Seven
pregnancies occurred among LNG-IUD users, all intrauterine.
No pregnancy occurred in the 1342 woman–years of
observation of the TCu380A and 681 of the LNG-IUD from
8 to 11 years, based on 682 TCu380A and 398 LNG-IUD users
starting the eighth year of use, respectively (Annex 1A).
The overall cumulative rate of method discontinuations
was higher in the LNG-IUD group than in the TCu380A
group throughout the 7 years (Table 1, Annex 1 A). There
were 129 expulsions of the TCu380A and 104 of the
LNG-IUD, with cumulative 7-year rates of 8.84 (0.77) and
8.18 (0.84) per 100, respectively (Table 1). Twenty-six
(20%) expulsions in the TCu380A group and 45 (43%) in the
LNG-IUD group were complete. One uterine perforation
happened with the LNG-IUD and none with the TCu380A.
Five LNG-IUD removals were due to diagnosis of PID, three
in the first 6 months of use. Two TCu380A IUD removals
occurred due to PID in the fifth and sixth year of use.
For each of the 7 years, the cumulative rate of method
discontinuation due to bleeding problems was higher in the
LNG-IUD than the TCu380A group (Table 1, Annex 1 A).
Amenorrhea and reduced bleeding were the main causes for
stopping use of the LNG-IUD while for the TCu380A it was
increased bleeding (Table 1). The rate of removal of the IUD
for reasons of pain was similar in both IUDs.
By seventh year of use, 68 women in the LNG-IUD group
and four in the TCu380A group had stopped the use of the IUD
for signs and symptoms compatible with those reported to be
associated with use of hormonal contraception (Table 1). The
most common reasons reported among LNG-IUD users were
weight gain (24 women) and ovarian cysts (12 women). Other
less frequent reasonswere dizziness/faintness and headaches. Six
TCu380A and 107 LNG-IUDswere removed for reason of “end
of IUD lifespan” in the sixth and seventh year. The rates of “other
device-related reasons” for IUD discontinuation were similar for
the two devices, the most frequent included wish to change to
another contraceptive method and complaints by the husband.
Nondevice-related reasons for method discontinuation
were higher in the LNG-IUD than in the TCu380A group
from year three to year seven (Table 1). The majority of these406 IUD removals were for wish to become pregnant (245,
60%) and for no further need (65, 16%).
Losses to follow-up were higher among women using
TCu380A than women with LNG-IUD, becoming statistically
significantly different from the fifth year onwards (Table 1).
Selected results of the analysis stratifying by Chinese and
non-Chinese centres are shown in Table 2 and Fig. 2 with
details in Annexes 1B and 1C. The analysis indicates some
important differences between the devices in the two groups of
centres. The rate of discontinuation due to increased bleeding
is higher for the LNG-IUD than for the TCu380A in Chinese
centres, while in non-Chinese centres, this pattern is reversed.
The cumulative pregnancy rates were generally higher in
Chinese than in non-Chinese centres. In both groups of centres,
the cumulative removal rates for amenorrhea were higher for
the LNG-IUD and were consistently higher in Chinese
compared to non-Chinese centres. For both types of IUDs,
non-Chinese centres had higher cumulative removal rates for
pain and for nondevice-related reasons than Chinese centres
through each year of the study. In non-Chinese compared to
Chinese centres, the overall discontinuation rates in users of the
TCu380A were higher from the first year and among users of
LNG-IUD from the second year of use. For both IUDs, the
losses of follow-up were higher in non-Chinese than in
Chinese centres throughout the duration of the study.
The results of the sensitivity analysis excluding the five
centres with the highest losses to follow-up showed very
similar results to those obtained when these five centres were
included in the analysis.
There were 15 diagnoses of ovarian cysts and four of
“adnexal mass”, 16 of which were in LNG-IUD users. One
woman was diagnosed with malignant breast tumour and
two with ovarian teratoma. Five women died during
participation in the study, two from traffic accidents and
one each from pulmonary and rectal carcinoma, and one
woman died from systemic lupus erythematosis.4. DiscussionThis study found the 52-mg LNG-IUD provided by
interval insertion to parous women to be highly efficacious
with very low cumulative pregnancy rates through 7 years
(Table 1, Annex 1 A), similar to the 3- and 5-year pregnancy
rates reported in other studies of IUDs with 46-mg, 52-mg and
60-mg LNG [7,9,17]. Sivin et al. [18] reported a 7-year
cumulative rate of 0.5 (1.0) for a 60-mg LNG-IUD. Three
smaller studies have reported no pregnancies during use of the
LNG-IUD in the sixth through the seventh year [19–21]. The
TCu380A IUD, also a very efficacious contraceptive, had a
7-year cumulative pregnancy rate of 2.45 (0.44) per 100. The
pregnancy rates for the TCu380A are significantly higher than
those of the LNG-IUD in this study, albeit that in a large
multicentre study coordinated by WHO, the pregnancy rates
of the TCu380A were somewhat lower than in the current
study, 1.0 (0.3), 1.4 (0.4) and 1.6 (0.4) per 100 at 3, 5 and
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French et al. [22] reported no significant difference in annual
pregnancy rates through 5 years between LNG-IUDs with
initial release of 20 microg and copper IUDs with N250-mm2
copper surface. In a European 1-year follow-up survey, the
pregnancy rate was significantly lower for the 52-mg
LNG-IUD compared to different copper-IUDs of which
N71% had copper surface areas of N300 mm2 [23].
Overall, the LNG-IUD had consistently higher rates of
method discontinuation than the TCu380 IUD (Table 1). In the
multicentre randomized studies by Sivin et al. [7] and by
Andersson et al. [17], the overall 5-year continuation of
LNG-IUDs and the copper-IUDs were 33.0 and 40.6 and 46.9
and 44.5 per 100, respectively. An observational study in the
US reported a 4-year continuation rate of 62.3 for LNG-IUD
and 64.2 per 100 for copper IUDs [24]. Amenorrhea and
reduced bleeding accounted for most of the difference of
method discontinuation in our study. The cumulative removal
rates for amenorrhea rose from 4.3 at 1 year to 26.1 per 100
women after 7 years of use, the latter rate being similar to the
24.6 (2.0) per 100 in the Population Council study [18].
However, the 5-year removal rate for amenorrhea in the
multicentre European study was 6.0 per 100 women [17], and
Backman et al. [25] reported from a survey in Finland that
amenorrhea was not associated with premature removal of the
LNG-IUD. In a US study, bleeding problems were not among
the main reasons for discontinuing the LNG-IUD [24].
In this study, the 7-year removal rate for amenorrhea in the
Chinese centres was nearly twice that of the non-Chinese centres
(31.0 compared with 15.6 per 100), these geographical
dissimilarities point to cultural differences in the acceptability
of amenorrhea but may also be associated with counselling
before starting and during use of the device. Moreover, attitudes
toward amenorrhea and reduced bleedingmay change over time.
The 7-year rates of IUD removals for pain were
similar for the two devices; other studies had inconsistent
findings for removal rates for pain among users of LNG
and copper IUDs [5–7,17,24,26–27]. In this WHO study
and the European studies of the LNG-IUD, the removal
rate for hormonal reasons was higher than that of the
comparator copper device [14,17]. This finding is not
unexpected as it is known that there is systemic absorption
of LNG from the LNG-IUD [28]. Nondevice-related reasons
for IUD removal accounted for a substantial proportion of
the discontinuations.
Sivin et al. [7,18] reported higher cumulative expulsion
rates for the 46-mg and 60-mg LNG-IUDs combined at 5
and 7 years of use, compared to the TCu380 Ag IUD.
Overall, we found similar expulsion rates for the two
IUDs, which is in agreement with findings of Andersson
et al. [17] and the 3-year cumulative expulsion rates for
LNG-IUD and copper IUDs recently reported by Madden
et al. [29].
Differences between Chinese and non-Chinese centres
have been noted in previous studies of different copper IUDs
coordinated of by WHO; in Chinese centres, the pregnancyrates have generally been higher while removal rates for
medical reasons have been lower compared to non-Chinese
centres [2,13], patterns also seen in the present study.
However, this comparison between a copper and a hormonal
IUD showed a substantial different pattern in the reasons for
IUD removal for bleeding problems. The cumulative discon-
tinuation rate at 7 years of the LNG-IUD for amenorrhoea was
almost double in Chinese centres compared with non-Chinese
centres. For the TCu380A IUD, these rates were negligible in
both types of centres. The 7-year cumulative discontinuation
rate for increased bleeding in the TCu380A group in
non-Chinese centres was almost three times that in the
Chinese centres, while for the LNG-IUD the rates were similar
in the two types of centres.
As expected the cumulative loss to follow-up was
lower with the new, experimental LNG-IUD than the
standard TCu380A. The sensitivity analysis excluding the
five centres with the highest losses to follow-up showed
similar results and patterns of discontinuation as the
analysis including all centres. A limitation of the current
study is that it is concerned with parous women. In
addition, during the time elapsed from the study, its
completion and publication, women's attitudes to amenor-
rhea and reduced bleeding associated with the LNG-IUD
may have changed.
Our data indicate that the 52-mg LNG-IUD and the
TCu380A are safe with very high contraceptive efficacy
through 7 years of use. The LNG-IUD is associated with
hormonal side effects and reduced bleeding including
amenorrhea. The reduced blood loss can be an advantage,
although it may not be acceptable in certain cultural settings
and can result in high removal rates.Funding
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